AA
CALA

AlphaMark Advisors’s Calithera Biosciences, Inc CALA Stock Holding History

AlphaMark Advisors’s Portfolio CALA Stock Details CALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-106
Closed -$11K – 575
2020
Q2 		$11K Buy
106
+32
+43% +$3.8K ﹤0.01% 358
2020
Q1 		$7K Buy
74
+15
+25% +$1.79K ﹤0.01% 353
2019
Q4 		$7K Hold
59
– – ﹤0.01% 379
2019
Q3 		$4K Hold
59
– – ﹤0.01% 425
2019
Q2 		$5K Hold
59
– – ﹤0.01% 421
2019
Q1 		$8K Sell
59
-57
-49% -$5.99K ﹤0.01% 357
2018
Q4 		$9K Hold
116
– – ﹤0.01% 328
2018
Q3 		$12K Hold
116
– – ﹤0.01% 331
2018
Q2 		$12K Buy
+116
New +$13.1K ﹤0.01% 348

Other funds holding CALA

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AlphaMark Advisors's CALA Position: Q3 2020 in Review

AlphaMark Advisors sold out of Calithera Biosciences, Inc (CALA) in Q3 2020, closing a stake of 106 shares — an estimated $11K sold.

AlphaMark Advisors first reported a position in CALA in Q2 2018 and held it in 9 quarters. The position peaked at $12K in Q3 2018. 97 funds tracked by Wall St. Rank hold CALA as of Q3 2020.

  • AlphaMark Advisors reported no remaining Calithera Biosciences, Inc position as of Q3 2020 after selling out during the quarter.
  • AlphaMark Advisors sold 106 Calithera Biosciences, Inc shares in Q3 2020, an estimated $11K.
  • AlphaMark Advisors first reported a position in Calithera Biosciences, Inc in Q2 2018 and held it in 9 quarters.
  • AlphaMark Advisors's Calithera Biosciences, Inc position peaked at $12K in Q3 2018.
  • 97 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q3 2020.

Based on AlphaMark Advisors's 13F filing for Q3 2020, filed 6 Nov 2020.